GlaxoSmithKline Partnering with Exscientia

GlaxoSmithKline Partnering with Exscientia

GlaxoSmithKline is partnering with privately-owned Exscientia to use artificial intelligence to help develop new drugs, according to a report from Reuters. The deal with Exscientia will allow GlaxoSmithKline to search drug candidates for up to 10 disease-related targets by using super computers and machine-learning systems to predict how molecules will behave. Exscientia’s artificial intelligence system could deliver drug candidates in “roughly one-quarter of the time and at one-quarter of the […]

Read More ˃